| Specific growth rate versus doubling time for quantitative characterization of tumor growth rate E Mehrara, E Forssell-Aronsson, H Ahlman, P Bernhardt Cancer research 67 (8), 3970-3975, 2007 | 256 | 2007 |
| Optimization of cell viability assays to improve replicability and reproducibility of cancer drug sensitivity screens P Larsson, H Engqvist, J Biermann, E Werner Rönnerman, ... Scientific reports 10 (1), 5798, 2020 | 154 | 2020 |
| Tumour therapy with radionuclides: assessment of progress and problems J Carlsson, EF Aronsson, SO Hietala, T Stigbrand, J Tennvall Radiotherapy and Oncology 66 (2), 107-117, 2003 | 153 | 2003 |
| A transplantable human carcinoid as model for somatostatin receptor-mediated and amine transporter-mediated radionuclide uptake L Kölby, P Bernhardt, H Ahlman, B Wängberg, V Johanson, A Wigander, ... The American journal of pathology 158 (2), 745-755, 2001 | 129 | 2001 |
| Low-energy electron emitters for targeted radiotherapy of small tumours P Bernhardt, E Forssell-Aronsson, L Jacobsson, G Skarnemark Acta Oncologica 40 (5), 602-608, 2001 | 128 | 2001 |
| Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours O Nilsson, L Kölby, B Wängberg, A Wigander, H Billig, L William-Olsson, ... British journal of cancer 77 (4), 632-637, 1998 | 128 | 1998 |
| Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111-DTPA-D-Phe1-octreotide P Andersson, E Forssell-Aronsson, V Johanson, B Wangberg The Journal of Nuclear Medicine 37 (12), 2002, 1996 | 127 | 1996 |
| Electron-and positron-emitting radiolanthanides for therapy: aspects of dosimetry and production H Uusijärvi, P Bernhardt, F Rösch, HR Maecke, E Forssell-Aronsson Journal of Nuclear Medicine 47 (5), 807-814, 2006 | 123 | 2006 |
| A method to obtain the same levels of CT image noise for patients of various sizes, to minimize radiation dose G Starck, L Lonn, A Cederblad, E Forssell-Aronsson, L Sjostrom, ... The British journal of radiology 75 (890), 140-150, 2002 | 122 | 2002 |
| (111) In-DTPA-D-Phe (1)-octreotide binding and somatostatin receptor subtypes in thyroid tumors EB Forssell-Aronsson, O Nilsson, SA Benjegard, L Kolby The Journal of Nuclear Medicine 41 (4), 636, 2000 | 120 | 2000 |
| Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters L Kölby, P Bernhardt, AM Levin-Jakobsen, V Johanson, B Wängberg, ... British journal of cancer 89 (7), 1383-1388, 2003 | 117 | 2003 |
| Systemic radionuclide therapy using indium-111-DTPA-D-Phe1-octreotide in midgut carcinoid syndrome M Fjälling, P Andersson, E Forssell-Aronsson, G Jakobina, V Johansson, ... Journal of Nuclear Medicine 37 (9), 1519-1521, 1996 | 117 | 1996 |
| A 1H magnetic resonance spectroscopy study in adults with obsessive compulsive disorder: relationship between metabolite concentrations and symptom severity G Starck, M Ljungberg, M Nilsson, L Jönsson, S Lundberg, T Ivarsson, ... Journal of neural transmission 115, 1051-1062, 2008 | 108 | 2008 |
| Stunning of iodide transport by 131I irradiation in cultured thyroid epithelial cells P Postgård, J Himmelman, U Lindencrona, N Bhogal, D Wiberg, G Berg, ... Journal of Nuclear Medicine 43 (6), 828-834, 2002 | 106 | 2002 |
| Renal function affects absorbed dose to the kidneys and haematological toxicity during 177Lu-DOTATATE treatment J Svensson, G Berg, B Wängberg, M Larsson, E Forssell-Aronsson, ... European journal of nuclear medicine and molecular imaging 42, 947-955, 2015 | 105 | 2015 |
| Chromogranin A as a determinant of midgut carcinoid tumour volume L Kölby, P Bernhardt, C Swärd, V Johanson, H Ahlman, ... Regulatory peptides 120 (1-3), 269-273, 2004 | 98 | 2004 |
| Biodistribution and dosimetry of free 211At, 125I− and 131I− in rats J Spetz, N Rudqvist, E Forssell-Aronsson Cancer Biotherapy and Radiopharmaceuticals 28 (9), 657-664, 2013 | 89 | 2013 |
| Differential expression of vesicular monoamine transporter (VMAT) 1 and 2 in gastrointestinal endocrine tumours AM Jakobsen, P Andersson, G Saglik, E Andersson, L Kölby, JD Erickson, ... The Journal of Pathology: A Journal of the Pathological Society of Great …, 2001 | 86 | 2001 |
| [177Lu-DOTA0-Tyr3]-Octreotate Treatment in Patients with Disseminated Gastroenteropancreatic Neuroendocrine Tumors: The Value of Measuring Absorbed … C Swärd, P Bernhardt, H Ahlman, B Wängberg, E Forssell-Aronsson, ... World journal of surgery 34, 1368-1372, 2010 | 83 | 2010 |
| Estimation of absorbed dose to the kidneys in patients after treatment with 177Lu-octreotate: comparison between methods based on planar scintigraphy M Larsson, P Bernhardt, JB Svensson, B Wängberg, H Ahlman, ... EJNMMI research 2, 1-13, 2012 | 77 | 2012 |
Peter BernhardtProfessor of Medical Physics, University of GothenburgVerified email at gu.se
